


Stabilis



Cefuroxime sodium



Noms commerciaux

Aksef	Turquie
Anaptivan	Grèce
Aprok	Irlande
Aprokam	Belgique, Grande Bretagne, Islande, Turquie
Axetine	Roumanie
Biociclin	Italie
Biofuroksyn	Pologne
Cefofix	Arabie Saoudite
Cefoprim	Italie
Cefurin	Italie
Cefurox	Argentine
Ceruxim	Grèce
Curocef	Autriche
Curoxim	Italie
Curoxima	Espagne
Curoxime	Portugal
Duxima	Italie
Galemin	Grèce
Gonif	Grèce
Ipacef	Italie
Itorex	Italie
Kefurox	Belgique
Keroxime	Brésil
Kesint	Italie
Lafurex	Italie
Multisef	Turquie
Nipogalin	Grèce
Normafenac	Grèce
Plixym	Pologne
Prokam	Espagne
Receant	Grèce
Supero	Italie
Tarsime	Pologne
Vekfazolin	Grèce
Ximaract	Belgique, Espagne, Grande Bretagne
Xorim	Pologne
Yokel	Grèce
Zetagal	Grèce
Zilisten	Grèce

Zinacef	Allemagne, Arabie Saoudite, Belgique, Brésil, Canada, Danemark, Etats Unis d'Amérique, Finlande, Grande Bretagne, Grèce, Norvège, Pays bas, Pologne, Slovénie, Suède, Suisse
Zinnat	France, Turquie
Zinocep	Italie



Stabilité des solutions

		15 mg/ml	25°C		48			644
		5 & 10 mg/ml	-10°C		30			636
		5 & 10 mg/ml	25°C		24			636
		5 & 10 mg/ml	5°C		30			636
		7,5 mg/ml	2-8°C		7			1452
		7,5 mg/ml	25°C		24			1452
		22,5 & 45 mg/ml	3°C		7			443
		30 & 60 mg/ml	-20°C		30			443
		5 & 10 mg/ml	-10°C		30			636
		5 & 10 mg/ml	25°C		24			636
		5 & 10 mg/ml	5°C		30			636
		6 mg/ml	25°C		24			1656
		6 mg/ml	4°C		7			1656
		15 mg/ml	-30°C		90			1958
		15 mg/ml	4°C		11			656
		15 mg/ml	4°C		15			1958
		15 mg/ml	-20°C		98			2008
		15 mg/ml	4°C		31			2095

		7,5 mg/ml	2-8°C		7			1452
		7,5 mg/ml	25°C		24			1452
		10 mg/ml	-18°C		120			3569
		10 mg/ml	-20°C		365			1972
		10 mg/ml	25°C		16			1972
		10 mg/ml	5°C		21			1972
		50 mg/ml	25°C		2			1813
		50 mg/ml	5°C		21			1813
		90 mg/ml	25°C		48			4284
		90 mg/ml	4°C		14			4284
		5 & 30 mg/ml	4°C		10			604
		10 mg/ml	-20°C		365			1972
		10 mg/ml	25°C		16			1972
		10 mg/ml	5°C		21			1972



Stabilité en mélange

		7,5 & 15 mg/ml	22°C		Aminophylline : 1 & 2 mg/ml	4	
		15 mg/ml	25°C		Clindamycin phosphate : 9 mg/ml	48	
		7,5 & 15 mg/ml	22°C		Theophylline : 0,8 mg/ml	4	
		7,5 & 15 mg/ml	22°C		Aminophylline : 1 & 2 mg/ml	4	
		7,5 & 15 mg/ml	22°C		Aminophylline : 1 & 2 mg/ml	4	
		7,5 mg/ml	4°C		Metronidazole : 5 mg/ml	7	






















































Facteur influençant la stabilité

				4284
				636



Compatibilités

			
	Cefuroxime sodium : 15 mg/ml Aciclovir sodium : 5 mg/ml		336
	Cefuroxime sodium : 30 mg/ml Alfentanil hydrochloride : 500 µg/ml		3380
	Cefuroxime sodium : 20 mg/ml Allopurinol sodium : 3 mg/ml		307
	Cefuroxime sodium : 30 mg/ml Amifostine : 10 mg/ml		3
	 Cefuroxime sodium Amikacin sulfate		3549
	 Cefuroxime sodium Amikacin sulfate		3687
	Cefuroxime sodium : 7,5 & 15 mg/ml Aminophylline : 1 & 2 mg/ml		96
	Cefuroxime sodium : 7,5 & 15 mg/ml Aminophylline : 1 & 2 mg/ml		96
	Cefuroxime sodium : 7,5 & 15 mg/ml Aminophylline : 1 & 2 mg/ml		96
	Cefuroxime sodium : 30 mg/ml Amiodarone hydrochloride : 6 mg/ml		1611
	Cefuroxime sodium : 100 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
	Cefuroxime sodium : 30 mg/ml Anidulafungin : 0.5 mg/ml		1982
	Cefuroxime sodium : 7.5 mg/ml Atracurium besylate : 0.5 mg/ml		402
	 Cefuroxime sodium : 100 mg/ml Azithromycine : 2 mg/ml		1800
	Cefuroxime sodium : 30 mg/ml Aztreonam : 40 mg/ml		99
	Cefuroxime sodium : 30 mg/ml Bivalirudin : 5 mg/ml		1713
	Cefuroxime sodium : 100 mg/ml Caffeine : 10 mg/ml		3964
	Cefuroxime sodium : 30 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
	 Cefuroxime sodium : 30 mg/ml Ciprofloxacin lactate : 2 mg/ml		285
	 Cefuroxime sodium : 30 mg/ml Cisatracurium besylate : 2 & 5 mg/ml		299
	Cefuroxime sodium : 15 mg/ml Clindamycin phosphate : 9 mg/ml		644
	Cefuroxime sodium : 90 mg/ml Cloxacillin sodium : 100 mg/ml		3012
	Cefuroxime sodium Dimenhydrinate		2087
	Cefuroxime sodium : 30 mg/ml Fenoldopam mesylate : 80 µg/ml		1803

	Cefuroxime sodium : 15 mg/ml Fentanyl citrate : 50 µg/ml		63
	Cefuroxime sodium : 30 mg/ml		301
	Cefuroxime sodium : 30 mg/ml Dexmedetomidine : 4 µg/ml		1712
	Cefuroxime sodium : 100 mg/ml Diltiazem hydrochloride : 1 & 5 mg/ml		198
	Cefuroxime sodium : 15 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
	Cefuroxime sodium : 30 mg/ml Docetaxel : 0.9 mg/ml		1754
	Cefuroxime sodium : 30 mg/ml Etoposide phosphate : 5 mg/ml		1410
	Cefuroxime sodium : 30 mg/ml		1415
	Cefuroxime sodium Erythromycin lactobionate		3674
	Cefuroxime sodium : 15 mg/ml Famotidine		397
	Cefuroxime sodium : 20 mg/ml Famotidine : 2 mg/ml		215
	Cefuroxime sodium : 30 mg/ml Fentanyl citrate : 50 µg/ml		3380
	Cefuroxime sodium : 20 mg/ml Filgrastim : 30 µg/ml		244
	Cefuroxime sodium : 37,5 mg/ml Flucloxacillin sodium : 20 mg/ml		1232
	Cefuroxime sodium : 30 mg/ml Fluconazole : 2 mg/ml		496
	Cefuroxime sodium : 30 mg/ml Fosfomycin : 30 mg/ml		4055
	Cefuroxime sodium : 37,5 mg/ml Furosemide : 1 mg/ml		1232
	Cefuroxime sodium : 100 mg/ml	RL	4603
	Cefuroxime sodium : 30 mg/ml Fludarabine phosphate : 1 mg/ml		492
	Cefuroxime sodium : 30 mg/ml Foscarnet sodium : 24 mg/ml		73
	Cefuroxime sodium : 30 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
	Cefuroxime sodium Gentamicin sulfate		3687
	Cefuroxime sodium Gentamicin sulfate		3643
	Cefuroxime sodium Gentamicin sulfate		3520
	Cefuroxime sodium : 30 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
	Cefuroxime sodium Heparin sodium : 10 & 50 UI/ml		3687
	Cefuroxime sodium : 30 mg/ml Hetastarch : 60 mg/ml		1721

		Cefuroxime sodium : 30 mg/ml Hydromorphone hydrochloride : 0.2 mg/ml		405
		Cefuroxime sodium : 30 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Cefuroxime sodium Kanamycin sulfate		3687
		Cefuroxime sodium : 100 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Cefuroxime sodium Lidocaine hydrochloride : 10 mg/ml		3687
		Cefuroxime sodium : 30 mg/ml Linezolid : 2 mg/ml		1925
		Cefuroxime sodium : 20 mg/ml Melphalan : 0.1 mg/ml		169
		Cefuroxime sodium : 100 mg/ml Meropenem : 50 mg/ml		4319
		Cefuroxime sodium : 7,5 mg/ml Metronidazole : 5 mg/ml		961
		Cefuroxime sodium Metronidazole		3594
		Cefuroxime sodium : 7.5 mg/ml Midazolam hydrochloride : 0.05 >> 0.4 mg/ml		1888
		Cefuroxime sodium : 15 mg/ml Midazolam hydrochloride : 1 mg/ml		176
		Cefuroxime sodium : 30 mg/ml Morphine sulfate : 1 mg/ml		405
		Cefuroxime sodium N-acetylcysteine : 200 mg/ml		3766
		Cefuroxime sodium : 100 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Cefuroxime sodium Netilmicin sulfate		3687
		Cefuroxime sodium : 30 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Cefuroxime sodium : 7.5 mg/ml Pancuronium bromide : 0.05 mg/ml		402
		Cefuroxime sodium Pantoprazole sodium		2090
		Cefuroxime sodium : 100 mg/ml Paracetamol : 10 mg/ml		4742
		Cefuroxime sodium : 30 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Cefuroxime sodium : 30 mg/ml Pethidine hydrochloride : 10 mg/ml		405
		Cefuroxime sodium : 62,5 mg/ml Phloroglucinol : 2,5 mg/ml		3791
		Cefuroxime sodium : 30 mg/ml Piritramide : 0.5 mg/ml		3380
		Cefuroxime sodium : 30 mg/ml Piritramide : 7.5 mg/ml		3380
		Cefuroxime sodium : 30 mg/ml Plazomicin sulfate : 24 mg/ml		4145

	Cefuroxime sodium Potassium chloride : 10 & 40 mEq/l		3687	
	Cefuroxime sodium : 30 mg/ml Propofol : 10 mg/ml		300	
	Cefuroxime sodium : 30 mg/ml Remifentanyl hydrochloride : 25 & 250 µg/ml		59	
	Cefuroxime sodium : 100 mg/ml Salbutamol sulfate : 1 mg/ml		3216	
	Cefuroxime sodium : 30 mg/ml Sargramostim : 10 µg/ml		335	
	Cefuroxime sodium Streptomycin sulfate		3687	
	Cefuroxime sodium : 30 mg/ml Sufentanil citrate : 0.005 mg/ml		3380	
	Cefuroxime sodium : 30 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801	
	Cefuroxime sodium : 30 mg/ml Tacrolimus : 1000 µg/ml		479	
	Cefuroxime sodium : 30 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827	
	Cefuroxime sodium : 30 mg/ml Temocilline : 83.33 mg/ml		2231	
	Cefuroxime sodium : 20 mg/ml Teniposide : 0.1 mg/ml		905	
	Cefuroxime sodium : 7,5 & 15 mg/ml Theophylline : 0,8 mg/ml		96	
		Cefuroxime sodium : 100 mg/ml Thiopental sodium : 25 mg/ml		3767
	Cefuroxime sodium : 30 mg/ml Thiotepa : 1 mg/ml		249	
	Cefuroxime sodium Tobramycin sulfate		3687	
	Cefuroxime sodium : 1 >> 150 mg/ml Vancomycin hydrochloride : 2 mg/ml		1674	
	Cefuroxime sodium : 1 mg/ml Vancomycin hydrochloride : 20 mg/ml		1674	
		Cefuroxime sodium : 10 >> 150 mg/ml Vancomycin hydrochloride : 20 mg/ml		1674
	Cefuroxime sodium : 7.5 mg/ml Vecuronium bromide : 0.1 mg/ml		402	
		Cefuroxime sodium : 20 mg/ml Vinorelbine tartrate : 1 mg/ml		84



Voie d'administration





Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
63	Revue	Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812.
73	Revue	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
96	Revue	Stewart JT, Warren FW, Johnson SM. Stability of cefuroxime sodium and aminophylline or theophylline. Am J Hosp Pharm 1994 ; 51: 809-811.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
176	Revue	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
215	Revue	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
285	Revue	Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255.

299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
397	Revue	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
402	Revue	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
405	Revue	Nieves-Cordero AL, Luciw HM, Souney PF. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1985 ; 42: 1108-1109.
443	Revue	Stiles ML, Allen LV, Fox JL. Stability of ceftazidime (with arginine) and of cefuroxime sodium in infusion-pump reservoirs. Am J Hosp Pharm 1992 ; 49: 2761-2764.
479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
604	Laboratoire	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
636	Revue	Das Gupta V, Stewart KR. Stability of cefuroxime sodium in some aqueous buffered solutions and intravenous admixtures. J Clin Hosp Pharm 1986 ; 11: 47-54.


644	Revue	Marble DA, Bosso JA, Townsend RJ. Compatibility of clindamycin phosphate with aztreonam in polypropylene syringes and with cefoperazone sodium, cefonicid sodium, and cefuroxime sodium in partial-fill glass bottles. Drug Intell Clin Pharm 1988 ; 22: 54-57.
656	Revue	Galanti LM, Hecq JD, Vanbeckbergen D, Jamart J. Long-term stability of cefuroxime and ceftazidime sodium in intravenous infusions. J Clin Pharm Ther 1996 ; 21: 185-189.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
961	Revue	Barnes AR. Chemical stabilities of cefuroxime sodium and metronidazole in an admixture for intravenous infusion. J Clin Pharm Ther 1990 ; 15: 187-196.
1232	Revue	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1452	Revue	Muller HJ, Howe K, Frank C, Haker I. Stability of ceftazidime, cefotiam, cefuroxime, ceftazidime, ceftioxcime, ceftioxcime, ceftioxcime and ceftazidime in normal saline solutions, stored in a new IV container made of Biofine*. Eur Hosp Pharm 2000 ; 6: 17-23.
1611	Revue	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1656	Revue	Faouzi A, Dine T, Luyckx M, Gressier B, Brunet C, Goudaliez F, Mallevais ML, Cazin M, Cazin JC. Stability and compatibility studies of cefaloridine, cefuroxime and ceftazidime with PVC infusion bags. Pharmazie 1994 ; 49: 425-427.
1674	Revue	Trissel LA, Gilbert DL, Martinez JF. Concentration dependency of vancomycin hydrochloride compatibility with beta-lactam antibiotics during simulated Y-site administration. Hosp Pharm 1998 ; 33: 1515-1522.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.

1800	Revue	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1813	Revue	Gupta VD. Chemical stability of cefuroxime sodium after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. Int J Pharm Compound 2003 ; 7, 4: 310-312.
1888	Revue	Janknegt R, Van den Berg TJ, De Jong M, Oldenhof HGJ, Steenhoek A. Compatibility study of midazolam. Ziekenhuisfarmacie 1986 ; 2: 45-48.
1925	Revue	Trissel LA, Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1958	Revue	Hecq JD, Schlessler V, Vanbeckbergen D, Jamart J, Galanti L. Effect of freezing, long-term storage and microwave thawing on the stability of cefuroxime sodium in 5% dextrose infusion polyvinyl chloride bags. EJHP Science 2005 ; 11: 23-25.
1972	Revue	Feutry, F., Simon, N., Genay, S., Lannoy, D., Barthelemy, C., Decaudin, B., Labalette, P., Odou, P. Stability of 10 mg/mL cefuroxime solution for intracameral injection in commonly used polypropylene syringes and new ready-to-use cyclic olefin copolymer sterile vials using the LC-UV stability-indicating method. Drug Dev Ind Pharm 2016 ; 42, 1: 166-174.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2008	Revue	Hecq JD, Boitquin LP, Vanbeckbergen DF, Jamart J, Galanti LM. Effect of the freezing conditions and microwave thawing power on the stability of cefuroxime in dextrose 5% infusion polyolefin bags at 4°C. Ann Pharmacotherapy 2005 ; 39: 1244-1248.
2087	Revue	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2095	Revue	Rodenbach, MP, Hecq JD, Vanbeckbergen D, jamart J, Galanti L. Stability of cefuroxime infusion: the brand-name drug versus a generic product. EJHP Science 2006 ; 12, 2: 32-34.
2109	Revue	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2231	Revue	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.


3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3380	Revue	Eckle V-S, Heim E, Hahn M, Grasshoff C. Incompatibility of Piritramide with Cephalosporins. Ann Pharmacotherapy 2013 ;47:426-427.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3520	Laboratoire	Cidomycin - Summary of product Characteristics. Sanofi 2011
3549	Laboratoire	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3569	Revue	Fleury-Souverain S, Sadeghipour F, Bonnabry P. Development of ready-to-use cefuroxime syringes for use in ophthalmology. EJHP 2014 ;21:34-38
3594	Laboratoire	Metronidazole (Flagyl®) - Summary of Product Characteristics Zentiva 2013
3643	Laboratoire	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Laboratoire	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3687	Laboratoire	Cefuroxime sodium - Summary of Product Characteristics Stravencon 2013
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3791	Poster	Sadou Yaye H, Burtet E, Hamel C, Aljhani R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015

3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4284	Revue	Vercheval C, Streel S, Servais A-C, Fillet M, Van Hees T. Stability of 90 mg/mL cefuroxime sodium solution for administration by continuous infusion. Journal of Chemotherapy 2018 ; 30, 6-8: 371-374.
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Stabilis


































































Cefuroxime sodium



Stabilité des préparations













		550 mg Zinacef®	Eau ppi >> 10 ml	-30°C		365			2682
		1500 mg Zinacef®	Eau distillée >> 30 ml	25°C		24			2683
		1500 mg Zinacef®	Alcool polyvinylique 1.4% Hydroxyéthylcellulose Chlorure de benzalkonium 0.004% Edétate de sodium 0.02% NaCl NaOH PH= 4.5-6 Eau distillée >> 30 ml	25°C		24			2683
		550 mg Zinacef®	Eau ppi >> 10 ml	25°C		24			2682
		550 mg Zinacef®	Eau ppi >> 10 ml	2°C		28			2682
		1500 mg Zinacef®	Eau distillée >> 30 ml	4°C		14			2683
		1500 mg Zinacef®	Alcool polyvinylique 1.4% Hydroxyéthylcellulose Chlorure de benzalkonium 0.004% Edétate de sodium 0.02% NaCl NaOH PH= 4.5-6 Eau distillée >> 30 ml	4°C		28			2683

		1500 mg Zinacef®	Hypromellose 0.25% Chlorhexidine acetate 0.0075% NaCl NaHCO3 Polysorbate 80 PH= 8-9 Eau distillée >> 30 ml	25°C		24			2683
		1500 mg Zinacef®	Hypromellose 0.30% NaCl KCl Borate de sodium Acide borique PH= 8.45 Eau distillée >> 30 ml	25°C		24			2683
		1500 mg Zinacef®	Hypromellose 0.25% Chlorhexidine acetate 0.0075% NaCl NaHCO3 Polysorbate 80 PH= 8-9 Eau distillée >> 30 ml	4°C		28			2683
		1500 mg Zinacef®	Hypromellose 0.30% NaCl KCl Borate de sodium Acide borique PH= 8.45 Eau distillée >> 30 ml	4°C		28			2683
		550 mg Zinacef®	Eau ppi >> 10 ml	25°C		24			2682
		550 mg Zinacef®	Eau ppi >> 10 ml	2°C		21			2682
		1 g ® = Biouroksym®	Eau ppi 99 g	4°C		27			3290
		1 g ® = Biouroksym®	Tampon citrate pH 6.25 - 302 mOsmol/L 96.1 g	4°C		15			3290
		1 g ® = Biouroksym®	Borate de phenylmercure 0,04% 2,5 g βphenylethylalcool 0.4 g Tampon citrate pH 6.25 - 302 mOsmol/L 96.1 g	4°C		15			3290
		1 g ® = Biouroksym®	Alcool polyvinylique η = 42 mPas pH 5.75 49.5 g Borate de phenylmercure 0.04% 2,5 g βphenylethylalcool 0.4 g Tampon citrate pH 6.05 - 581 mOsmol/L 49.5 g	4°C		18			3290
		1 g ® = Biouroksym®	Alcool polyvinylique η = 42 mPas pH 5.75 49.5 g Tampon citrate pH 6.05 - 581 mOsmol/L 49.5 g	4°C		18			3290
		5 g ® = Biouroksym®	Eau ppi 95 g	4°C		27			3290
		5 g ® = Biouroksym®	Tampon citrate pH 6.28- 160 mOsmol/L 96.1 g	4°C		15			3290
		5 g ® = Biouroksym®	Borate de phenylmercure 0,04% 2,5 g βphenylethylalcool 0.4 g Tampon citrate pH 6.28- 160 mOsmol/L 92.1 g	4°C		15			3290
		5 g ® = Biouroksym®	Alcool polyvinylique η = 42 mPas pH 5.75 49.5 g Tampon citrate pH 6.25 - 302 mOsmol/L 49.5 g	4°C		27			3290

?		5 g ® = Biouroksym®	Alcool polyvinylique $\eta = 42$ mPas pH 5.75 Borate de phenylmercure 0.04% 2.5g 4°C β phenylethylalcool 0.4 g Tampon citrate pH 6.25 - 302 mOsmol/L 46.05 g	 5 g				3290
---	--	---------------------	--	---	--	--	--	------



Facteur influençant la stabilité

					2682
	20°C				3041
	20°C				3290
	4,5 < pH < 7,3				3041












Bibliographie

	Type	Source
2682	Revue	Oldham GB. Formulation and stability of cefuroxime eye-drops. Int J Pharm Pract 1991 ; 1: 19-22.
2683	Revue	Hebron B, Scott H. Shelf life of cefuroxime eye-drops when dispensed in artificial tear preparations. Int J Pharm Pract 1993 ; 23: 163-167.
3041	Revue	Kodym A, Zawisza T, Taberska J , Kukula H. Physicochemical and microbiological properties of eye drops containing cefuroxime. Acta Pol Pharm 2006 ; 63: 293-299.
3290	Revue	Kodym A, Wisniewski A, Kniola D, Olejniczak M. Stability of cefuroxime in 1% and 5% buffered eye drops determined with HPLC method. Acta Pol Pharm 2011 ; 68, 4: 555-564.



Dictionnaire

 Antibiotique	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Verre
 NaCl 0,9% ou glucose 5%	 Lumière
 Heure	 A l'abri de la lumière
 Jour	 Non précisée
 Chlorure de sodium 0,9%	 Polyvinyl chlorure
 Eau pour préparation injectable	 Glucose 5%
 Polyéthylène	 Polyoléfine
 Seringue polypropylène	 Elastomère en polyisoprène
 AT-Closed vial®	 Stabilité en mélange
 Solvant	 Molécule
 Chlorure de sodium 0,45%	 NaCl 0,45% Glucose 5%
 Aucun	 Facteur influençant la stabilité
 Provoque	 Diminution de la stabilité
 Micro-ondes	 Dégradation
 Compatibilités	 Compatible
 Instabilité chimique	 Incompatible
 Incompatibilité non précisée	 Précipitation immédiate
 Précipitation en 24 heures	 Nutrition parentérale (mélange binaire)
 Nutrition parentérale (mélange ternaire)	 RL Ringer lactate
 Solvant spécifique	 Turbidité immédiate
 Précipitation en 8 heures	 Précipitation en 1 heure
 Voie d'administration	 Intraveineuse
 Perfusion intraveineuse	 Intramusculaire
 Bibliographie	 Collyre

 Stabilité des préparations	 Origine
 Excipient	 Flacon injectable
 Flacon plastique	 Non précisé
 Augmentation	 Augmentation stabilité
 Dictionnaire	